[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![PrismMarketView Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1257318598386696195.png) PRISM MarketView [@PrismMarketView](/creator/twitter/PrismMarketView) on x 4675 followers
Created: 2025-07-09 12:31:03 UTC

Emergent BioSolutions (NYSE: $EBS) secured a $51.9M contract modification to supply more VIGIV—its smallpox vaccine complication treatment—to the U.S. government. Analysts at HCW view this as continued validation of Emergent’s position as a trusted biodefense partner, following last month’s $62.4M award for its botulism antitoxin. .@EmergentBio

![](https://pbs.twimg.com/media/GvaneG6WQAAUdIl.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1942924460446675407/c:line.svg)

**Related Topics**
[$624m](/topic/$624m)
[$519m](/topic/$519m)
[$ebs](/topic/$ebs)
[new york stock exchange](/topic/new-york-stock-exchange)
[prism](/topic/prism)

[Post Link](https://x.com/PrismMarketView/status/1942924460446675407)